Subsequent to January 31, 2017, the Company entered into an agreement with an agent regarding the replacement of the Company’s existing loan. The Company also intends to complete an equity private placement within the next month. We are examining both non-dilutive and dilutive arrangements, with a preference for non-dilutive alternatives, in the following priority: co-development, licensing, rights (on indications or potential follow-on compounds, for instance) or other partnering arrangements, private placements and/or public offerings (equity and/or debt); therefore, we frequently engage in such discussions. These conditions result in a material uncertainty which may cast significant doubt on our ability to continue as a going concern.

    With this one line alone "  The company ENTERED INTO AN AGREEMENT WITH AN AGENT REGUARDING THE REPLACEMENT OF THE COMPANIES EXISTING LOAN" mind you we don't now the complete details , Resverlogix has been significantly derisked and value increased ( Hopefully with new agent NO Intellectual property (IP ) in deal , just equity and tax relief . 

I too believe any additional equity financing will be north of Hepalink PP . I believe $ 3.00 Canadian which would also provide the necessary requirement for a Nasdaq listing 

Stock ( great news release today !)